NOTCH3 and acute lymphoblastic leukemia: In support of this exclusive ability, we observed an higher cell survival decrease of Juglone-treated T-ALLs expressing Notch3 (TALL-1, Molt3, DND41, SIL-ALL, P12-I) when compared to Notch3 negative/low cells (Jurkat, KOPKT1, Ke37) (Supplementary Fig. S11), thus suggesting that Notch3 expression levels may dictate the T-ALLs sensitivity to Juglone.